首页> 外文期刊>Current topics in medicinal chemistry >Agonistic and antagonistic bivalent ligands for serotonin and dopamine receptors including their transporters.
【24h】

Agonistic and antagonistic bivalent ligands for serotonin and dopamine receptors including their transporters.

机译:血清素和多巴胺受体(包括其转运蛋白)的拮抗和拮抗二价配体。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

This review deals with the literature (1982-2006) concerning bivalent ligands for dopamine (D) and serotonin (5-HT) receptors, as well as for their respective transporters. The design, synthesis, and pharmacological evaluation of bivalent agonists and antagonists for dopamine and serotonin receptors have been successfully pursued. Increased potencies for 5-HT(1B/1D) receptor agonists were achieved as well as improved selectivities. At these receptors, selectivity seems to depend strongly on spacer length, whereas the improved affinities seem to be based on the presence of two pharmacophores within one molecule. Intrinsic activities and pharmacokinetic properties may differ from those of the respective monovalent ligands. Additionally, improved central nervous system penetration was achieved. Bivalent dopamine receptor agonists and antagonists can exhibit selectivity profiles different from their monomeric analogues with no loss in potency. For dopamine antagonists, affinities depend strongly on spacer length. For agonistic dimers different pharmacokinetic properties were observed. Bivalency was also applied to inhibitors of monoamine re-uptake transporters. Selectivity profiles and affinities depend strongly on the length of the alkylene-spacer: For some dimeric inhibitors the norepinephrine transporter (NET) and the dopamine transporter (DAT) affinities changed gradually, but for the serotonin transporter (SERT) a pentamethylene spacer showed the highest potency. Because the bivalent ligand approach has just begun to be applied to these versatile, therapeutically important targets, many advances in affinity enhancement, as well as the achievement of novel selectivity profiles and improved pharmacokinetics can be expected.
机译:这篇综述涉及有关多巴胺(D)和5-羟色胺(5-HT)受体及其各自转运蛋白的二价配体的文献(1982-2006)。对多巴胺和5-羟色胺受体的二价激动剂和拮抗剂的设计,合成和药理学评价已经成功地进行。提高了5-HT(1B / 1D)受体激动剂的效力,并提高了选择性。在这些受体上,选择性似乎很大程度上取决于间隔区的长度,而改善的亲和力似乎是基于一个分子中存在两个药效基团。内在活性和药代动力学特性可能与相应的单价配体不同。另外,实现了改善的中枢神经系统渗透。二价多巴胺受体激动剂和拮抗剂可以表现出不同于其单体类似物的选择性,而效能没有损失。对于多巴胺拮抗剂,亲和力在很大程度上取决于间隔物的长度。对于激动剂二聚体,观察到不同的药代动力学性质。双亲性也适用于单胺再摄取转运蛋白的抑制剂。选择性分布和亲和力很大程度上取决于亚烷基间隔基的长度:对于某些二聚抑制剂,去甲肾上腺素转运蛋白(NET)和多巴胺转运蛋白(DAT)亲和力逐渐变化,但对于5-羟色胺转运蛋白(SERT),五亚甲基间隔基显示最高效力。由于二价配体方法刚刚开始应用于这些多功能的,治疗上重要的靶标,因此可以期待亲和力增强方面的许多进步,以及实现新的选择性分布和改善的药代动力学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号